Trial Profile
A Randomized Active-Controlled Study of AMG 162 in Breast Cancer Subjects With Bone Metastasis Who Have Not Previously Been Treated With Bisphosphonate Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Bisphosphonates
- Indications Breast cancer; Cancer metastases
- Focus Pharmacodynamics
- Sponsors Amgen
- 16 Jun 2009 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.
- 01 Jun 2008 Results presented at the Annual Meeting of the American Society of Clinical Oncology 2008.
- 17 Sep 2005 New trial record.